Relevant bibliographies by topics / IRINOTECAN CANCER TREATMENT

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'IRINOTECAN CANCER TREATMENT'

Author: Grafiati
Published: 26 October 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'IRINOTECAN CANCER TREATMENT.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "IRINOTECAN CANCER TREATMENT"

1

Ando, Koji, Yuho Ebata, Eiji Oki, Tomoharu Yoshizumi, and Ajit Bharti. "Development of new therapeutic strategies to enhance the effectiveness of irinotecan in colorectal cancer treatment." Journal of Clinical Oncology 43, no. 4_suppl (2025): 217. https://doi.org/10.1200/jco.2025.43.4_suppl.217.

Full text
Abstract:
217 Background: Chemotherapy plays an important role in the treatment of colorectal cancer. Irinotecan, a topoisomerase I inhibitor, is used in therapies such as FOLFIRI and FOLFOXIRI. However, many patients become resistant to irinotecan, and the detailed mechanisms of resistance are not fully understood. The aim is to develop new therapeutic strategies by elucidating the mechanisms of irinotecan resistance. Methods: We used in vitro approach to demonstrate the mechanism of topoI degradation. Immunohistochemistry staining was used to explore the biomarker for irinotecan, Finally, in vivo appr
APA, Harvard, Vancouver, ISO, and other styles
2

Aoki, Masahiko, Hirokazu Shoji, Hiroshi Imazeki, et al. "The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer." Journal of Clinical Oncology 37, no. 4_suppl (2019): 124. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.124.

Full text
Abstract:
124 Background: Nivolumab has demonstrated a survival benefit as a single agent in patients with advanced gastric cancer (AGC) refractory to, or intolerant of, two or more previous regimens in phase III study (ATTRACTION-2). However, an acceleration of tumor growth during immunotherapy, (hyperprogressive disease: HPD), was reported in advanced cancers treated with immunotherapy. The frequency and outcome of HPD in AGC comparing between immunotherapy and cytotoxic agents are little known. The aim of this study was to clarify the prevalence and background of HPD in patients treated with nivoluma
APA, Harvard, Vancouver, ISO, and other styles
3

Falcone, Alfredo, Antonello Di Paolo, Gianluca Masi, et al. "Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients." Journal of Clinical Oncology 19, no. 15 (2001): 3456–62. http://dx.doi.org/10.1200/jco.2001.19.15.3456.

Full text
Abstract:
PURPOSE: To investigate the sequence effect of irinotecan and a 48-hour infusion of fluorouracil (5-FU) modulated by leucovorin (LV) on the plasma pharmacokinetics of irinotecan and its metabolites, the toxicity profile of this combination, and irinotecan’s maximum-tolerated dose (MTD). PATIENTS AND METHODS: Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV. The reverse sequence was used after 21 days for the second cycle. 5-FU 3,500 mg/m2 was preceded by l-LV 250 mg/m2. Ir
APA, Harvard, Vancouver, ISO, and other styles
4

Ahire, Eknath D., and Sanjay J. Kshirsagar. "Irinotecan's molecular mechanisms against cancer: a primary system biology and chemoinformatics approach for novel formulation development." Current Issues in Pharmacy and Medical Sciences 38, no. 1 (2025): 31–37. https://doi.org/10.12923/cipms-2025-0005.

Full text
Abstract:
Cancer is the third most common type of cancer generally. It affects 6.1% of the entire world’s population and kills 9.2% of all people of both sexes. Even though people with colon cancer have a number of chemotherapies and surgeries to choose from, the disease often returns after the first treatment. AutoDockVina by PyRx 0.8v was used to do molecular docking. The admetSAR2.0 web server was employed for ADMET analysis. The MolSoft and ADVERPred tools were applied to predict the drug's potential for abuse and its potential for side effects. The anti-tumor effects of irinotecan may be aimed at t
APA, Harvard, Vancouver, ISO, and other styles
5

Vanhoefer, Udo, Andreas Harstrick, Wolf Achterrath, Shousong Cao, Siegfried Seeber, and Youcef M. Rustum. "Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview." Journal of Clinical Oncology 19, no. 5 (2001): 1501–18. http://dx.doi.org/10.1200/jco.2001.19.5.1501.

Full text
Abstract:
PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I–interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer. RESULTS: Irinotecan was investigated as second-line chemotherapy after prior treatment with fluorouracil (FU)-based regimens in two large randomized phase III trials comparing ir
APA, Harvard, Vancouver, ISO, and other styles
6

Ali, Selda, Denisa-Mihaela Nedelcu, Radu Serescu, and Roxana Silvia Bumbăcea. "Successful Desensitization to Irinotecan in a Patient with Metastatic Esophageal Squamous Cell Carcinoma and a History of Anaphylaxis in Response to Irinotecan—Case Report and Literature Review." Journal of Clinical Medicine 13, no. 24 (2024): 7824. https://doi.org/10.3390/jcm13247824.

Full text
Abstract:
Background: Irinotecan is a topoisomerase I inhibitor used for the treatment of various cancers, such as gastrointestinal, pancreatic, pulmonary, ovarian, and cervical cancers. Among chemotherapy agents, it represents a rare trigger of drug hypersensitivity reactions, with few cases being reported until today. Methods: We present the case of a patient with metastatic esophageal cancer and a history of irinotecan-induced grade IV (WAO classification) anaphylaxis. An IgE-mediated reaction was confirmed in our case, as evidenced by a positive intradermal skin test result, and we carried out a suc
APA, Harvard, Vancouver, ISO, and other styles
7

Ghodeswar, Bindu, and Santosh Chhajed. "Irinotecan Resistance Mechanisms in Cancer: Challenges and Opportunities." INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY 14, no. 02 (2024): 1099–105. http://dx.doi.org/10.25258/ijddt.14.2.74.

Full text
Abstract:
Irinotecan, a topoisomerase I inhibitor, has been widely used in the treatment of various solid tumors, including colorectal, lung, and pancreatic cancers. However, its efficacy is often limited by the development of resistance mechanisms within cancer cells. Understanding these resistance mechanisms is crucial for improving treatment outcomes and developing effective therapeutic strategies. This review article provides a comprehensive overview of the mechanisms underlying irinotecan resistance in cancer. Key resistance mechanisms discussed include the overexpression of drug efflux pumps, acti
APA, Harvard, Vancouver, ISO, and other styles
8

Radajewska, Anna, Helena Moreira, Dorota Bęben, et al. "Combination of Irinotecan and Melatonin with the Natural Compounds Wogonin and Celastrol for Colon Cancer Treatment." International Journal of Molecular Sciences 24, no. 11 (2023): 9544. http://dx.doi.org/10.3390/ijms24119544.

Full text
Abstract:
Colorectal cancers are one of the leading cancers worldwide and are known for their high potential for metastasis and resistance to therapy. The aim of this study was to investigate the effect of various combination therapies of irinotecan with melatonin, wogonin, and celastrol on drug-sensitive colon cancer cells (LOVO cell line) and doxorubicin-resistant colon cancer stem-like cells (LOVO/DX cell subline). Melatonin is a hormone synthesized in the pineal gland and is responsible for circadian rhythm. Wogonin and celastrol are natural compounds previously used in traditional Chinese medicine.
APA, Harvard, Vancouver, ISO, and other styles
9

Kockaya, Guvenc, Mine Polat, Albert Wertheimer, et al. "Treatment cost of metastatic colon cancer in Turkey." Farmeconomia. Health economics and therapeutic pathways 14, no. 1 (2013): 19–25. http://dx.doi.org/10.7175/fe.v14i1.472.

Full text
Abstract:
OBJECTIVES: Colon cancer is the third most common in the top cancer incidence list in Europe. In Europe 212,000 patients die every year due to colon cancer. In Turkey 120,000-130,000 new cancer patients are diagnosed every year, 7.1% of whom are diagnosed to have developed colon cancer. Metastases will occur in up to 50% of the patients who are newly diagnosed. Survival appears to be further prolonged to more than 20 months with new pharmaceuticals; however, these new pharmaceuticals increase the total cost of care. The aim of this study is to estimate the cost implications of new colon cancer
APA, Harvard, Vancouver, ISO, and other styles
10

Aoki, Masahiko, Hirokazu Shoji, Kengo Nagashima, et al. "Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer." ESMO Open 4, no. 3 (2019): e000488. http://dx.doi.org/10.1136/esmoopen-2019-000488.

Full text
Abstract:
BackgroundNivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotecan.MethodsThe subjects of this retrospective study were patients with AGC with measurable lesions, and their tumour growth rates (TGR) during nivolumab or irinotecan were compared with those during prior therapy. HPD was defined as an increase in TGR more than twofold.Results34 and 66 patients receive
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "IRINOTECAN CANCER TREATMENT"

1

Schiel, Marissa Ann. "Human carboxylesterase 2 splice variants expression, activity, and role in the metabolism of irinotecan and capecitabine /." Thesis, Connect to resource online, 2009. http://hdl.handle.net/1805/1905.

Full text
Abstract:
Thesis (Ph.D.)--Indiana University, 2009.<br>Title from screen (viewed on August 28, 2009). Department of Biochemistry and Molecular Biology, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): William Bosron. Includes vita. Includes bibliographical references (leaves 102-111).
APA, Harvard, Vancouver, ISO, and other styles
2

Hinkle, David T. "CORRELATING IRINOTECAN AND CAPECITABINE TREATMENT FOR COLORECTAL CANCER TO GENE EXPRESSION, POLYMORPHISMS, AND CLINICAL OUTCOMES." Thesis, 2011. http://hdl.handle.net/1805/2510.

Full text
Abstract:
Indiana University-Purdue University Indianapolis (IUPUI)<br>Colorectal cancer is the third most common type of cancer and the third most common cause of cancer-related mortality. There are three types of treatment available to patients, either individually or in combination. Treatments are radiation, chemotherapy, and surgery. In a Phase II clinical trial at IUSM, a multimodality approach was chosen. The patients with locally advanced rectal cancer received preoperative treatment with capecitabine and irinotecan (CPT-11) combination followed by chemoradiation with capecitabine and finally sur
APA, Harvard, Vancouver, ISO, and other styles
3

DAS, NIVEDITA. "IN SILICO SCREENING OF QUERCETIN ANALOGUES AS POTENTIAL INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA FOR DIARRHEA MITIGATION IN IRINOTECAN CANCER TREATMENT." Thesis, 2023. http://dspace.dtu.ac.in:8080/jspui/handle/repository/19909.

Full text
Abstract:
Diarrhea can be caused due to many reasons in an oncological patient. It could be due to radiation therapy, graft vs host infections, chemotherapeutic agents. Early diagnosis of causative agent can help to prevent diarrhea in cancer patients. Chemotherapeutic agents such as 5 fluorouracil with leucovorin, capecitabine and irinotecan are main causative agent of diarrhea. Loperamide and Octreotide are two recommended treatments for chemotherapy induced diarrhea. Loperamide can only treat grade 1 or 2 diarrhea, it becomes ineffective in severe cases of diarrhea. Octreotide is especi
APA, Harvard, Vancouver, ISO, and other styles
4

Chen, Ming-Cheng, and 陳明正. "Molecular Mechanism of Resistance to Irinotecan in LoVo Colon Cancer Cells, Pharmacological Mechanism of Targeted Treatment by Thymoquinone and Mechanisms of Cancer Stem Cells and miRNAs." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/97204020698622003607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Messerer, Corrie Lynn. "Liposomal encapsulation of irinotecan and potential for the use of liposomal drug in the treatment of liver metastases associated with advanced colorectal cancer." Thesis, 2002. http://hdl.handle.net/2429/13284.

Full text
Abstract:
Colorectal cancer is the second leading cause of cancer mortality in North America, primarily because of a high incidence of hepatic metastases, which are relatively unresponsive to the systemic chemotherapy. Irinotecan, a camptothecin analogue recently approved for used in conjunction with 5-fluorouricil/leucovorin, is a marginal improvement but toxic and by no means curative. Liposomal drug formulations are argued to be more effective at treating liver-localised carcinomas when compared with their free drug counterparts, because of their intrinsic affinity for the liver and extended lifespan
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "IRINOTECAN CANCER TREATMENT"

1

National Institute for Clinical Excellence. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. NICE, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

M, Lloyd Jones, and National Co-ordinating Centre for HTA (Great Britain), eds. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Core Research on behalf of NCCHTA, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lloyd, Jones M., National Co-ordinating Centre for HTA (Great Britain), and Health Technology Assessment Programme, eds. A Rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. NCCHTA, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "IRINOTECAN CANCER TREATMENT"

1

Saltz, Leonard B. "Irinotecan in the Treatment of Colorectal Cancer." In Colorectal Cancer. Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-160-2_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wagner, Lars. "Pediatric Neuroblastoma: Treatment with Oral Irinotecan and Temozolomide." In Pediatric Cancer. Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-2418-1_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fiorentini, Giammaria, Silvia Ricci Lucchi, Petros Giovanis, Maurizio Cantore, Stefano Guadagni, and Giorgio Papiani. "Phase I Clinical Study of Irinotecan (CPT-11) Hepatic Arterial Infusion Chemotherapy in Hepatic Metastases from Colorectal Cancer: Preliminary Results." In Multi-Treatment Modalities of Liver Tumours. Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0547-1_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kaan Güren, Ali, and Osman Köstek. "Treatment of Metastatic Colorectal Cancer: Beyond Progression." In Advances in Diagnosis and Therapy of Colorectal Carcinoma [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.1004840.

Full text
Abstract:
Metastatic colorectal cancer is a major health problem, accounting for 8.1% of US cancer cases. Although 5-FU-oxaliplatin-irinotecan-based chemotherapy combination regimens and targeted therapies have increased 5-year survival rates to around 13%. The still low rate of this rate increases the demand for new treatment options. Advances in the discovery of tumor biology have made it possible to better define the subtypes and resistance mechanisms of metastatic colorectal cancer. In this regard, personalized treatment strategies are becoming increasingly important in the treatment of advanced sta
APA, Harvard, Vancouver, ISO, and other styles
5

Oteyola, Ayodeji Ojo, Raffaele Pilla, Folasade Adesola Ola-Oladimeji, and Omotayo Fagbuaro. "Natural Products Application and Combination Therapy in Colorectal Cancer Treatment." In Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-9258-8.ch004.

Full text
Abstract:
Colorectal cancer (CRC) is one of the common types of cancer affecting humans. The treatment of CRC involves surgery and chemotherapy. CRC treatment using the conventional chemotherapeutics has a negative burden on the patient's health as a result of high toxicity, occurrence of side effects, and drug resistance. Therefore, there is a pressing need to discover more effective and efficient approaches and drugs for treating CRC. This chapter will shed more light on the conventional treatment of colorectal cancer. This chapter discusses the natural products that have anti-CRC effects such as the
APA, Harvard, Vancouver, ISO, and other styles
6

Karmane Sumou, Ingrid, and Xianghong Peng. "Patient Selection and Treatment Consideration in Metastatic Colorectal Cancer." In Cancer Metastasis - Mechanism, Diagnosis, Prognosis and Targeted Therapy [Working Title]. IntechOpen, 2025. https://doi.org/10.5772/intechopen.1009297.

Full text
Abstract:
Colorectal cancer (CRC) is a leading cause of cancer-related mortality globally, ranking as third and second in terms of cancer incidence and mortality, posing a significant economic burden for patients, families, and the society. There are about 2 million new cases and 1 million deaths worldwide in 2020. Intensive efforts have been made in the chemotherapy, targeted therapy, and immunotherapy drugs to palliate symptoms and prolong life, with significant progress, increasing the median overall survival (OS). Standard 1st and 2nd-line pharmacological management of metastatic colorectal cancer (
APA, Harvard, Vancouver, ISO, and other styles
7

Gangar, Mukesh, Sandeep Goyal, Aditya Kulkarni, and Charu Kamal Yerneni. "Human Topoisomerases and Caspases: Important Targets in Cancer Therapy." In Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815124699123010011.

Full text
Abstract:
Cancer has always remained a major challenge to humanity with its rising morbidity and mortality rate making it uncontrollable. Current treatments for cancer offer limited efficacy and suffer from serious side effects. With a focus on making treatment safer and more effective, there is a need to identify novel targets and potent drugs for these targets. Recent years have witnessed significant progress in the discovery of targeted cancer therapy. On-going research in this field suggests that human topoisomerases and caspases are important molecular drug targets for anti-cancer drug development.
APA, Harvard, Vancouver, ISO, and other styles
8

Kulke, Matthew H., and Robert J. Mayer. "Management Options: Metastatic Gastric Carcinoma." In Gastrointestinal Oncology. Oxford University PressNew York, NY, 2003. http://dx.doi.org/10.1093/oso/9780195133721.003.0027.

Full text
Abstract:
Abstract Approximately 50% of patients with gastric adenocarcinoma have metastatic disease at the time of their initial presentation. Metastatic disease also develops in most patients who undergo potentially curative resection. Systemic cytotoxic chemotherapy remains the most effective treatment modality for patients with metastatic gastric cancer. Studies in the past 30 years have demonstrated that several chemotherapeutic agents are active in this disease, including 5-fluorouracil (5-FU), doxorubicin, cisplatin, and mitomycin C. More recent studies have shown that oral analogues of 5-FU, as
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "IRINOTECAN CANCER TREATMENT"

1

Davidson, David, Yunzhe Wang, Raquel Aloyz, and Lawrence Panasci. "Abstract 4692: ABT-888 synergizes treatment of colon cancer cell lines with irinotecan." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4692.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Morano, Federica, Salvatore Corallo, Ludovic Barault, et al. "Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Westover, David, Xiang Ling, Xiaojun Liu, et al. "Abstract 829: The novel camptothecin derivative and IAP inhibitor FL118 is an effective treatment for irinotecan-refractory colorectal cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gregori, T., A. Vergati, and A. Cavaliere. "1ISG-004 Pharmacoeconomic analysis of liposomal irinotecan as second-line treatment for advanced pancreatic cancer versus standard therapy folfirinox." In 29th EAHP Congress, Copenhagen, Denmark, 12-13-14 March 2025, Person centred pharmacy — Navigating digital health. British Medical Journal Publishing Group, 2025. https://doi.org/10.1136/ejhpharm-2025-eahp.12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Giever, Thomas A., Paul S. Ritch, James P. Thomas, et al. "Abstract 813: A combination of cisplatin, irinotecan, and paclitaxel (CIP) as frontline treatment of patients with metastatic esophageal cancer (mEC)." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-813.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sachdev, Jasgit C., Ramesh K. Ramanathan, Natarajan Raghunand, et al. "Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-01-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Klinz, Stephan, Jinzi Zheng, Raquel De Souza, et al. "Abstract B47: Nanoliposomal irinotecan (nal-IRI) is an active treatment and reduces hypoxia as measured through longitudinal imaging using [18F]FAZA-PET in an orthotopic patient-derived model of pancreatic cancer." In Abstracts: AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.panca16-b47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Moulder, S., M. Mita, C. Bradley, C. Rocha, and L. Harris. "Abstract P6-15-01: A Phase 1b Study To Assess the Safety and Tolerability of the PARP Inhibitor Iniparib (BSI-201) in Combination with Irinotecan for the Treatment of Patients with Metastatic Breast Cancer (MBC)." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p6-15-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sachdev, JC, RK Ramanathan, N. Raghunand, et al. "Abstract OT3-02-14: A phase 1 study in patients with metastatic breast cancer to evaluate the feasibility of magnetic resonance imaging with ferrumoxytol as a potential biomarker for response to treatment with nanoliposomal irinotecan (nal-IRI, MM-398)." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-ot3-02-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'IRINOTECAN CANCER TREATMENT' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography